|
Pharmaceutical Product Development, LLC (PPD) is a global contract research organization (CRO) providing discovery, development and post-approval services as well as compound partnering programs. The company’s clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. PPD is mainly known for conducting drug development for its clients, it also invests in developing new products through its compound partnering program. ==History== PPD was founded by Fred Eshelman, Pharm.D., as a one-person consulting firm in 1985. The following year he expanded the company's scope to include development services and relocated operations from Maryland to North Carolina. *July 1985: Fred Eshelman, Pharm.D., founds PPD as a one-person consulting firm based in his home in Maryland. *1986: Eshelman expands the company and relocates operations to Wilmington, North Carolina. *Jan. 1989: The company incorporates in North Carolina. *Jan. 1996: PPD issues its initial public stock offering and begins trading on the Nasdaq National Market System under the symbol PPDI. *Oct. 2005: PPD’s board of directors adopts an annual cash dividend policy. *July 2009: The company promotes Eshelman to executive chairman and names David Grange chief executive officer. *Jan. 2010: The company commemorates the 25th anniversary of its founding. *June 2010: PPD spins off its compound partnering division as a new and independent publicly traded company, Furiex Pharmaceuticals. *May 2011: David Grange retires as chief executive officer of PPD. *Sept. 2011: PPD’s board of directors names Raymond Hill as PPD’s new chief executive officer. *Dec. 2011: The company is acquired by affiliates of The Carlyle Group and affiliates of Hellman & Friedman in an all-cash transaction valued at approximately $3.9 billion. *May 2012: PPD’s board of directors names David Simmons as chairman and CEO. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Pharmaceutical Product Development」の詳細全文を読む スポンサード リンク
|